Plain-English translation of NCT05574387 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a medication commonly used to treat diabetes, can help improve ulcerative colitis when added to your regular treatment. Ulcerative colitis causes painful inflammation and bleeding in the colon, and current treatments don't work well enough for everyone. Researchers believe this medication might help your body better manage inflammation and improve how your gut functions.
Current treatments for ulcerative colitis help some patients, but many people still struggle with ongoing symptoms and flare-ups. This study exists to find new ways to make treatment more effective by combining this medication with standard therapy.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll take mesalamine (your standard ulcerative colitis medication) three times daily. Depending on which group you're randomly assigned to, you may also take the additional medication twice daily. The study will compare how well people do on standard treatment alone versus standard treatment plus the added medication. Your doctor will monitor your symptoms and inflammation over time.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Egypt
Sponsor
Tanta University
Collaborators
Principal Investigator Mostafa Mahmoud Bahaa El-Dien Pharmacy Practice Department- Horus University
Enrollment target
~46 participants
Started
January 2023
Primary completion
December 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mostafa Bahaa, PhD
Tanta University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.